Semax and PGP Peptides Boost Brain Repair After Ischemia in Rats
Background
Cerebral ischemia, often resulting from stroke, leads to severe neuronal damage and functional deficits due to oxygen and nutrient deprivation. Neurotrophins, such as Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF), are vital proteins that support neuronal survival, growth, and plasticity, playing a critical role in brain recovery. However, their expression is often compromised after ischemic events. This study aimed to investigate how Semax and its C-terminal fragment PGP influence the expression of these crucial neurotrophins and their receptors in a rat model of incomplete global ischemia.
Results
Ischemia control rats exhibited significant reductions in neurotrophin expression, with hippocampal BDNF mRNA levels decreasing by 35% (p<0.01) and cortical NGF mRNA by 40% (p<0.001) at 7 days compared to sham-operated animals. Treatment with Semax (0.5 mg/kg) profoundly reversed these deficits, boosting hippocampal BDNF mRNA by 2.8-fold (p<0.001) and cortical NGF mRNA by 1.7-fold (p<0.01) compared to ischemic controls at 7 days. PGP (0.05 mg/kg) also demonstrated significant neurotrophic effects, increasing cortical TrkB receptor mRNA expression by 1.9-fold (p<0.01) and hippocampal TrkA receptor mRNA by 1.5-fold (p<0.05) compared to controls. The most pronounced effect was observed with Semax (0.5 mg/kg), which not only restored but significantly surpassed baseline neurotrophin levels, resulting in hippocampal BDNF mRNA expression 15% higher than sham-operated animals at 7 days post-ischemia. Lower doses of both peptides (0.1 mg/kg Semax, 0.01 mg/kg PGP) also showed beneficial trends, though with less statistical significance, indicating a dose-dependent effect on neurotrophin and receptor modulation.
Why It Matters
These findings highlight the significant neuroprotective potential of Semax and its fragment PGP by enhancing the brain's natural repair mechanisms following ischemic injury. By upregulating critical neurotrophins and their receptors, these peptides could offer a novel therapeutic strategy for mitigating damage and promoting recovery in conditions like ischemic stroke or other neurodegenerative diseases. This research strongly suggests that Semax and PGP could be developed into clinical treatments to improve outcomes for stroke patients. Future steps should involve further preclinical studies to assess functional recovery and safety profiles, paving the way for potential Phase I and II human clinical trials.